NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of “Moderate Buy” from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $38.25.

A number of equities research analysts have recently weighed in on the company. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Finally, Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd.

NRx Pharmaceuticals Stock Performance

NRXP opened at $4.42 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $4.59. The company has a market capitalization of $160.14 million, a P/E ratio of -4.06 and a beta of 2.14. The stock has a fifty day moving average of $2.78 and a 200-day moving average of $2.37.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $19.43 million. On average, equities research analysts predict that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ethos Financial Group LLC raised its stake in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after purchasing an additional 4,000 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares in the last quarter. State Street Corp raised its stake in NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares in the last quarter. Sjbenen Advisory LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter valued at about $41,000. Finally, Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals News Roundup

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a loss of $0.23 from a prior forecast of a $0.13 profit, implying weaker short-term performance than previously expected. NRx Pharmaceuticals stock page
• Negative Sentiment: The firm also reduced near-term quarterly estimates, including Q2 2026 to $(0.05), Q3 2026 to $(0.06), and Q4 2026 to $(0.07), reinforcing concerns that losses may persist before growth improves. NRx Pharmaceuticals stock page
• Neutral Sentiment: Despite the cuts, HC Wainwright still expects a turnaround later on, with FY2027 EPS estimated at $0.67, FY2028 at $2.49, and FY2029 at $4.51, suggesting long-term upside remains in the analyst’s view. NRx Pharmaceuticals stock page

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.